Notes to editor
This press release accompanies a presentation at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
The hashtag for ESC Congress 2025 is #ESCCongress
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
Funding: The trial was principally funded by the Canadian Institutes of Health Research, Canadian Arrhythmia Network, ACT Network and Government of Alberta, with unrestricted support from GE Healthcare and Medtronic.
Disclosures: Professor Exner reports consulting to Medtronic and GE Healthcare, Abbott Medical and Boston Scientific.
References and notes:
1‘REFINE ICD: Efficacy of ICD therapy in higher risk post-MI patients with better-preserved LV function’ presented during HOT LINE 3 on 30 August 2025 at 11:45 to 11:55 in Madrid (Main Auditorium).
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.